文献速递脑血管病神经重症与神经感染

镁与脑出血血肿扩大:FAST-MAG随机试验分析

Magnesium and Hematoma Expansion in Intracerebral Hemorrhage: A FAST-MAG Randomized Trial Analysis.
PubMed 文献 · Stroke · 2023-12-21

FAST-MAG试验的脑出血患者探索性二次分析显示,镁治疗组中较高血清镁水平与血肿扩大减少(校正OR 0.64每mg/dL,95%CI 0.42-0.93)和早期神经功能恶化减少(校正OR 0.54每mg/dL,95%CI 0.33-0.82)相关,而安慰剂组无此关联。作者认为镁可能具有止血效应,但仅见于镁治疗组,需保持均衡并开展专门试验。

要点

  • 镁治疗组中较高血清镁水平与血肿扩大减少相关(校正OR 0.64每mg/dL)。
  • 镁治疗组中较高血清镁水平与早期神经功能恶化减少相关(校正OR 0.54每mg/dL)。
  • 安慰剂组中血清镁水平与血肿扩大或神经功能恶化均无关联。

核心结论

  • 镁可能表现出止血效应,但该效应仅在FAST-MAG镁治疗组中可观察到。
  • 作者认为应保持均衡,并需要开展专门试验。

研究设计与样本

  • FAST-MAG(Field Administration of Stroke Therapy-Magnesium)是一项在院前对急性临床卒中综合征给予硫酸镁的实用性临床试验,纳入包括脑出血在内的患者。
  • 本分析为探索性二次分析,比较治疗组与安慰剂组,并按治疗组和安慰剂组分层,使用单变量检验和校正逻辑回归分析血肿扩大与神经功能恶化。
  • 自发性脑出血患者381例;安慰剂组可获得的系列神经影像学检查较少(123例[65.4%] vs 145例[75.1%];P=0.038)。
  • 有可用必要数据的患者为镁治疗组104例和安慰剂组85例(年龄64.9[13.0]岁;67.7%为男性)。

主要发现

  • 血肿扩大定义为24小时内血肿体积增加≥3 mL;早期神经功能恶化定义为从到院至住院第4天格拉斯哥昏迷量表下降≥1分。
  • 镁治疗组中,较高镁水平与较少血肿扩大相关(校正OR 0.64每mg/dL,95%CI 0.42-0.93)。
  • 镁治疗组中,较高镁水平与较少神经功能恶化相关(校正OR 0.54每mg/dL,95%CI 0.33-0.82)。
  • 安慰剂组中,镁水平与血肿扩大或神经功能恶化均无关联。

关键数值与推荐

  • 血肿扩大定义为24小时内血肿体积增加≥3 mL。
  • 早期神经功能恶化定义为从到院至住院第4天格拉斯哥昏迷量表下降≥1分。
  • 镁治疗组:较高镁水平与血肿扩大减少相关,校正OR 0.64每mg/dL(95%CI 0.42-0.93)。
  • 镁治疗组:较高镁水平与神经功能恶化减少相关,校正OR 0.54每mg/dL(95%CI 0.33-0.82)。
  • 安慰剂组:镁水平与血肿扩大或神经功能恶化均无关联。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为镁可能表现出止血效应,但该效应仅在FAST-MAG镁治疗组中可观察到,应保持均衡并需要开展专门试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational studies suggest that magnesium may have hemostatic effects. FAST-MAG (Field Administration of Stroke Therapy-Magnesium) was a pragmatic clinical trial of magnesium sulfate administered prehospital for acute clinical stroke syndromes and included patients with intracerebral hemorrhage. Exploratory secondary analysis by the treatment group found no reduction in hematoma expansion (HE) associated with magnesium treatment in intracerebral hemorrhage but did not consider serum magnesium levels achieved. We analyzed FAST-MAG intracerebral hemorrhage data for associations between serum magnesium level, HE, and early neurological deterioration, accounting for groupwise biases. METHODS: HE was defined as hematoma volume increase ≥3 mL within 24 hours and early neurological deterioration as ≥1-point Glasgow Coma Scale decline from arrival to hospital day 4. Comparing treatment and placebo groups confirmed biased availability of neuroimaging data. Therefore, HE and neurological deterioration were analyzed and stratified by treatment and placebo groups using univariate tests and adjusted logistic regression. RESULTS: Spontaneous intracerebral hemorrhage was present in 381 patients. Placebo patients had fewer serial neuroimaging studies available (123 [65.4%] versus 145 [75.1%]; P=0.038). Necessary data were available in 104 magnesium- and 85 placebo-treated patients (age, 64.9 [13.0] years; 67.7% male). In the magnesium group, higher magnesium level was associated with less HE (adjusted odds ratio, 0.64 per mg/dL [95% CI, 0.42-0.93]) and less neurological deterioration (adjusted odds ratio, 0.54 per mg/dL [95% CI, 0.33-0.82]). In the placebo group, magnesium level was not associated with either HE or neurological deterioration. CONCLUSIONS: Magnesium may exhibit a hemostatic effect that was only observable in the FAST-MAG magnesium treatment group. Equipoise should be maintained, and specific trials are needed. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00059332.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Liotta EM, Maas MB, Prabhakaran S, et al. Magnesium and Hematoma Expansion in Intracerebral Hemorrhage: A FAST-MAG Randomized Trial Analysis. Stroke. 2023. PMID: 38126183. doi:10.1161/STROKEAHA.123.043555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。